



NDA 20-971/S-017

Arent Fox, PLLC
1050 Connecticut Avenue, NW
Washington, DC 20036-5339

Attention: Wayne Matelski
Counsel to and Official Correspondent for Deproco, Inc.

Dear Mr. Matelski:

Please refer to your supplemental new drug application dated June 22, 2006, received June 23, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Septocaine® (Articaine Hydrochloride 4% (40 mg/mL) with Epinephrine 1:100,000 Injection).

This “Changes Being Effected” supplemental new drug application provides for a change to the cartridge and carton labeling to reflect the new trade name “Septocaine® with epinephrine 1:100,000.”

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, cartridge and carton labeling).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-971/S-017.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Allison Meyer, Regulatory Project Manager, at (301) 796-1258.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, MD
Director
Division of Anesthesia, Analgesia and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Bob Rappaport
11/9/2006 06:08:25 PM